Gland Pharma stock
GLAND.NSNSEGland Pharma Limited, HealthcareISIN INE068V01023
70Score 70 out of 100, Strong
Price and trend
78 / 100
Price history
+80% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 41% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 84).
The price is at its 52-week high. Largest decline in 6 years: 79% (August 2021 to May 2023).
Chart figures for advanced users
- SMA 50$31.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)84
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.97
- The lowest closing price of the last twelve months.
- Resistance$35.17
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Gland Pharma Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $5.8B, is number 40 of 77 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $683.5M (up 14.5% year on year) and earnings of $109.19M (up 47.1%).
- For fiscal 2027, analysts expect on average revenue of $800.57M (up 17.1%) and adjusted earnings per share of $0.88 (up 32.3%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 132 of 702 in Healthcare, median 53.
- The P/E is 44.2 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 37.7).
- Our model puts fair value at $23.21, with the price 52% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $365.76M, financial debt $26.7M.Stability 91
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 76
- Analysts expect strong earnings growthUp 18.1% a year through 2029 (estimates from 12 analysts).
Weaknesses
- Above fair valuePrice 52% above the fair value of $23.21.Valuation 28
- Margin fallingOperating margin 18.8%, average of the prior years 32.2% (to 2025).
- Richly valuedP/E 44.2, Drug Manufacturers (Specialty & Generic) median 32.5, own median 37.7.Valuation 28
Its standout strengths are momentum and stability, while growth and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $17.85 and expensive above $33.15 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $20.51 (cash-flow model) and $25.90 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $21.57, at 11.6% it would be $25.56.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 23.1% on the twelve months before. Revenue has grown strongly since 2017, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 30%, operating 19%, net 16%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Jan 2027in 76 days
- Last reported
- 6 Nov 2026EPS reported $0.19 (expected $0.18)above expectations
Analyst estimates
Earnings estimates have barely changed since 30 Oct 2026.
- Earnings per share
- $0.88+1.6%
- Revenue
- $800.57M+1.1%
- Earnings per share
- $1.07+1.7%
- Revenue
- $914.53M+0.9%
MEQIRI has stored the estimates since 30 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Gland Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Alkem LaboratoriesALKEM.NS $6.74B65
- Lantheus HoldingsLNTH $6.62B76
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
- Apotex HealthAPTX.TO $6.17B68
- Sumitomo Pharma4506.T $5.54B57
- Ipca LaboratoriesIPCALAB.NS $5.12B69
- Laboratorios Farmaceuticos RoviROVI.MC $3.98B82
- Siegfried HoldingSFZN.SW $3.75B54
ETFs that hold Gland Pharma
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EM Small Cap UCITS ETFEUNI | 0.08% | 0.74% | €279.38M |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.04% | 0.32% | €17.98M |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.01% | 0.18% | €37.98B |
Show 2 more
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.01% | 0.18% | €5.26B |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.00% | 0.07% | €8.95B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.